ATE322477T1 - 3-epi-vitamin d2 verbindungen und ihre anwendungen - Google Patents

3-epi-vitamin d2 verbindungen und ihre anwendungen

Info

Publication number
ATE322477T1
ATE322477T1 AT98921249T AT98921249T ATE322477T1 AT E322477 T1 ATE322477 T1 AT E322477T1 AT 98921249 T AT98921249 T AT 98921249T AT 98921249 T AT98921249 T AT 98921249T AT E322477 T1 ATE322477 T1 AT E322477T1
Authority
AT
Austria
Prior art keywords
vitamin
compounds
epi
beta
applications
Prior art date
Application number
AT98921249T
Other languages
English (en)
Inventor
Satayanarayana G Reddy
Original Assignee
Woman & Infants Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Woman & Infants Hospital filed Critical Woman & Infants Hospital
Application granted granted Critical
Publication of ATE322477T1 publication Critical patent/ATE322477T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/59Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/5929,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/18Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT98921249T 1997-05-16 1998-05-15 3-epi-vitamin d2 verbindungen und ihre anwendungen ATE322477T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4664197P 1997-05-16 1997-05-16

Publications (1)

Publication Number Publication Date
ATE322477T1 true ATE322477T1 (de) 2006-04-15

Family

ID=21944565

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98921249T ATE322477T1 (de) 1997-05-16 1998-05-15 3-epi-vitamin d2 verbindungen und ihre anwendungen

Country Status (8)

Country Link
US (1) US6017908A (de)
EP (1) EP0981514B1 (de)
JP (1) JP2002506429A (de)
AT (1) ATE322477T1 (de)
AU (1) AU744471B2 (de)
CA (1) CA2288710A1 (de)
DE (1) DE69834109T2 (de)
WO (1) WO1998051664A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3146969T (pt) * 1999-04-23 2018-10-18 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
HUP0200812A3 (en) * 1999-04-23 2003-07-28 Leo Pharm Prod Ltd Vitamin d analogues and their pharmaceutical use
EP1233942A2 (de) * 1999-12-02 2002-08-28 The Penn State Research Foundation Behandlung von entzündlichen darmerkrankungen mit vitamin d-verbindungen
US6358939B1 (en) * 1999-12-21 2002-03-19 Northern Lights Pharmaceuticals, Llc Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease
WO2001091794A2 (en) 2000-05-30 2001-12-06 Virginia Commonwealth University Vitamin d3 analogs as radiosensitizers for the treatment of cancer
US20020019011A1 (en) * 2000-07-07 2002-02-14 Stockwell Brent R. Methods for identifying combinations of entities as therapeutics
US7351869B2 (en) * 2002-11-18 2008-04-01 Teva Pharmaceutical Industries Ltd Crystallization method for purification of calcipotriene
JP2006525367A (ja) * 2003-04-30 2006-11-09 ビオクセル エッセ ピ ア ジェミニビタミンd3化合物及びその使用方法
CA2528508A1 (en) * 2003-06-06 2004-12-16 Combinatorx Incorporated System and method for multidimensional evaluation of combinations of compositions
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
AU2005216651A1 (en) 2004-03-01 2005-09-09 Bioxell Spa Treatment of interstitial cystitis with vitamin D compounds
CA2586679A1 (en) 2004-11-12 2006-05-18 Bioxell Spa Combined use of vitamin d derivatives and anti-proliferative agents for treating bladder cancer
US20080064669A1 (en) * 2006-08-29 2008-03-13 Rakefet Cohen Stable pharmacologically active compositions including vitamin D-containing and corticosteroid compounds with low pH compatibility
CA2981549A1 (en) * 2009-01-27 2010-08-05 Berg Llc Vitamin d3 and analogs thereof for alleviating side effects associated with chemotherapy
CN106265695B (zh) 2009-08-14 2021-05-07 博格有限责任公司 用于治疗脱发的维生素d3及其类似物
CN112156097A (zh) 2013-05-29 2021-01-01 博格有限责任公司 使用维生素d预防或减轻化疗诱发的脱发
DE102013215580A1 (de) * 2013-08-07 2015-02-12 Orgentec Diagnostika Gmbh 25-OH Vitamin D Derivate zur Bestimmung von Vitamin D Metaboliten

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4038272A (en) * 1975-10-20 1977-07-26 Hoffmann-La Roche Inc. Stereospecific syntheses of 24r,25- and 24s,25-dihydroxycholesterol and alkanoyl derivatives thereof
US4021423A (en) * 1976-03-08 1977-05-03 Hoffmann-La Roche Inc. Syntheses of 24R,25- and 24S,25-dihydroxycholecalciferol
US4595776A (en) * 1983-03-21 1986-06-17 Hoffmann-La Roche Inc. Synthesis of 1α,25-dihydroxyergocalciferol
GB2139627B (en) * 1983-05-09 1987-02-04 Wisconsin Alumni Res Found 1 25-dihydroxylated vitamin d2 compounds and intermediates in the preparation thereof
JPS6144860A (ja) * 1984-08-10 1986-03-04 Taisho Pharmaceut Co Ltd 1α.25−ジヒドロキシ−26.27−ジメチルビタミンD↓3
US4804502A (en) * 1988-01-20 1989-02-14 Hoffmann-La Roche Inc. Vitamin D compounds
US5145846A (en) * 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US5104864A (en) * 1988-08-02 1992-04-14 Bone Care International, Inc. Method for treating and preventing loss of bone mass
US5547947A (en) * 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
US5401733A (en) * 1993-10-01 1995-03-28 Hoffmann-La Roche Inc. Stable and active metabolites of 1,25-dihydroxy-16-ene-cholecalciferol
US5428029A (en) * 1993-11-24 1995-06-27 Hoffmann-La Roche Inc. Vitamin D3 fluorinated analogs
ZA95906B (en) * 1994-02-07 1996-08-06 Res Developments Foundation Non-viral vector
SG70009A1 (en) * 1996-05-23 2000-01-25 Hoffmann La Roche Vitamin d3 analogs
NO971934L (no) * 1996-05-23 1997-11-24 Hoffmann La Roche Flourinerte vitamin D3 -analoger

Also Published As

Publication number Publication date
JP2002506429A (ja) 2002-02-26
US6017908A (en) 2000-01-25
DE69834109D1 (de) 2006-05-18
EP0981514B1 (de) 2006-04-05
DE69834109T2 (de) 2007-04-19
AU744471B2 (en) 2002-02-21
EP0981514A1 (de) 2000-03-01
WO1998051664A1 (en) 1998-11-19
AU7390398A (en) 1998-12-08
CA2288710A1 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
ATE322477T1 (de) 3-epi-vitamin d2 verbindungen und ihre anwendungen
FI952797A0 (fi) D-vitamiinianalogin uusi kiteinen muoto
AU1497997A (en) Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
AU1083992A (en) Formulations of d-cycloserine as cognitive enhancers
ES2196630T3 (es) Isotiazolcarboxiamidas y su empleo para la proteccion de las plantas.
HUP0001232A2 (hu) Béta-amiloid peptid kibocsátást és/vagy szintézist gátló cikloalkil-, laktám-, laktonszármazékok, és ezek tio-analógjai, valamint e vegyületeket tartalmazó gyógyászati készítmények
WO1998051663A3 (en) 3-epi compounds of vitamin d3 and uses thereof
SG49228A1 (en) Use of 2-amino-6-A-propyl-amino-4,5,6,7- tetrahydrobenzothiazole(pramipexol) as a antidepressant activity
FI961233A0 (fi) Katekolin syntetisointi biomassaperäisistä hiililähteistä
ES2192031T3 (es) Nuevas amidas aromaticas, su procedimiento de preparacion y su aplicacion como medicamentos.
GB9725750D0 (en) Compound
GB2331987B (en) Polycyclic sulphamate inhibitors of oestrone sulphatase
PT100961A (pt) Oximas de azabiciclo-arilacetileno e -arilenino como agentes colinergicos e composicoes farmaceuticas que as contem
ATE228980T1 (de) Verwendung von alkoholen als additive für putze und/oder mörtel
ES2119874T3 (es) Nuevos derivados de elipticina, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
BR0011261A (pt) Composição oral compreendendo perlita, e, uso de perlita
MY141507A (en) Slider block radial compliance mechanism with integral deflection bearing
ES2046923A1 (es) Procedimiento para la estabilizacion de elastomeros.
FI951588A0 (fi) Öljykoostumuksia
AR004484A1 (es) Nuevas 1,2,3,4-tetrahidro-2-naftalenaminas fenilo-sustituidas en el anillo aromatico, su preparacion, sus aplicaciones terapeuticas y las composicionesfarmaceuticas que las contienen.
ES2103104T3 (es) Nuevos compuestos di- y poliaminicos utiles en la preparacion de poliuretanos.
ATE227122T1 (de) Stabilisierte tablettenformulierung
DK0904272T3 (da) Dihydrobenzofuran og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler
MX9303970A (es) COMPUESTOS ESTEROIDALES DE ANILLO A DE 17Ó Y 17ß-ALQUILCETONA-3-CARBOXIAROMATICO.
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties